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Abstract 
Improper cervical function may lead premature or late-term birth. The RhoA/Rho-kinase 
(ROCK) signalling pathway takes part in cellular functions including smooth muscle 
contraction. No information is available about the cervical expression of the RhoA/ROCK 
system during pregnancy. Our aim was to detect the mRNA and protein expression of ROCK 
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enzymes in rat cervices and to evaluate the effects of RhoA/ROCK inhibitors on cervical 
resistance. 
The mRNA and protein expressions of RhoA, ROCK I and II were measured in non-pregnant, 
pregnant and postpartum rat cervices and during parturition by Real-time qPCR and Western 
blot. The cervical resistance modifying effects of RhoA (simvastatin) and ROCK (fasudil, Y-
27632) (10
-6
M) were investigated in tissue bath experiments. 
RhoA mRNA was increased on post-partum day 3, while the RhoA protein expression was 
decreased near and during parturition. ROCK I mRNA and protein expressions were 
fluctuating with a decrease in protein expression during parturition. ROCK II mRNA and 
protein expressions were sharply reduced during parturition. Simvastatin increased the 
cervical resistance on pregnancy days 20 and 22 while Y-27632 and fasudil reduced the 
resistance on pregnancy days 20.  
The decrease in RhoA/ROCK expression near parturition may take part in cervical ripening, 
especially in the final processes leading to delivery. ROCK inhibitors might be potential drug 
candidates to treat insufficient cervical ripening late-term pregnancies. The effect of 
simvastatin possibly due to its unique smooth muscle contracting activity in pregnant cervix. 
Compounds with simvastatin-like action might be new drug candidates for preterm cervical 
ripening. 
Key word: cervical ripening, RhoA/ROCK pathway, pregnancy, simvastatin, fasudil, 
pregnancy 
1. Introduction  
The cervix undergoes extensive changes during pregnancy. This remodelling is driven by 
several factors including the alteration of the hormonal (Stjernholm et al., 1996) and 
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prostaglandin (Hertelendy and Zakar, 2004) levels, the decreased collagen concentration by 
the activation of matrix metalloproteinases (Ludmir and  Sehdev, 2000) and cytokines 
(interleukin-1β and interleukin-8) (Winkler et al., 1998). At the end of the gestational period, 
the cervix is softened, shortened and dilated (Chwalisz and Garfield, 1997)  contributing to 
the parturition in parallel with the increase in myometrium contractions. Not only premature 
myometrial contraction but also early cervical ripening can be responsible for premature 
labour (Vink et al., 2016). On the other hand, delayed or insufficient cervical ripening can be 
one of the reasons for post term delivery and caesarean birth especially in obese mothers 
(Carlson et al., 2015). 
Ras homologue protein A (RhoA) is a monomer GTP-binding protein belonging to the Rho 
subfamily of the Ras superfamily (Ridley, 2001). Some proteins that have been identified as 
interacting directly with RhoA include mDia, rhophilin, rhotekin, citron kinase and Rho-
kinases (Bustelo et al., 2007). Rho-associated coiled-coil containing kinase (ROCK) is the 
main effectors of RhoA (Shimokawa and Takeshita, 2005). There are two isoforms of Rho-
kinase: ROCK I, and ROCK II (Fukata et al., 2001). The RhoA/Rho-kinase signalling 
pathway takes part in several cellular functions including cell adhesion, proliferation, motility 
and migration (Wettschureck and Offermanns, 2002) smooth muscle contraction (Kimura et 
al., 1996) and stress fibre formation (Kawano et al., 1999). The GTP-binding RhoA activates 
the Rho-kinases. These kinases phosphorylate the myosin phosphatase and myosin light 
chain. These processes together are responsible for smooth muscle contraction (Kaneko-
Kawano et al., 2012). Pregnancy reduces the role of the RhoA/ROCK system in rat uterine 
artery contractions. The irregularity of this system may be one of the reasons for vascular-
origin disorders during pregnancy including preeclampsia (Goulopoulou et al., 2012). 
Additionally, the RhoA-ROCK system is involved in apoptotic processes in several organs 
(e.g. kidney, liver, heart) (Wang et al., 2018; Ding et al, 2016; Niermann et al., 2016). The 
4 
 
apoptotic process is also a part of cervical ripening at the end of pregnancy (Hassan et al., 
2006), thus this is another reason to investigate the RhoA-ROCK system in cervical ripening. 
In our previously published paper we found a significant increase in RhoA and ROCK 
expressions during labour. Both RhoA and ROCK inhibitors had an inhibitory action on 
myometrial contractions that makes them potential candidates for the treatment of premature 
contractions (Domokos et al, 2017). However, no information is available about the cervical 
expressions and pharmacological responsiveness of RhoA, ROCK I and ROCK II during 
pregnancy.  
Our aim was to detect the mRNA and protein expression of RhoA, ROCK I and ROCK II in 
non-pregnant, pregnant, parturient and in post-partum rat cervices by Real-time qPCR and 
Western blot analysis. Furthermore, we investigated the role of the RhoA/Rho-kinase pathway 
in cervical resistance using RhoA inhibitor (simvastatin) and Rho-kinase inhibitors (Y-27632 
and fasudil) in non-pregnant, 20- and 22-day pregnant rat cervices. 
2. Material and methods 
2.1. Ethical approval 
The animals were treated in accordance European Communities Council Directives 
(2010/63/EU) and the Hungarian Act for the Protection of Animals in Research (Article 32 of 
Act XXVIII). All experiments were carried out with the approval of the National Scientific 
Ethical Committee on Animal Experimentation (registration number: IV/198/2013). 
 
2.2. Housing, handling and mating of the animals 
Sprague-Dawley rats (Charles-River Laboratories, Budapest, Hungary) were kept under 
standard conditions(temperature: 22±3ºC, 12 h light/12 h darkness cycle; relative humidity: 
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30-70%),Standard rodent pellet diet (Charles-River Laboratories, Budapest, Hungary) with 
tap water were available ad libidum. The female (180-200 g) and male (240-260 g) rats were 
mated in a special mating cage. A timer controlled, movable metal door separated the spaces 
for the female and male rats. The door was opened before dawn (4.00 a.m.). Within 4-5 h 
after the possibility of mating, vaginal smears were taken for sperm searching under a 
microscope at a magnification of 1200. If the search proved positive, the female rats were 
separated as 1
st 
day pregnant animals. 
2.3. Collection of cervical tissues for RT-PCR and Western blot studies 
The non-pregnant, pregnant and postpartum rats were terminated by CO2 inhalation, while the 
foetuses were terminated by cervical dislocation. Cervical tissues were removed from non-
pregnant, pregnant (gestational days 5, 15, 18, 20 and 22) and postpartum (1, 3 and 5 days 
after delivery) animals. During labour the cervices were dissected always after delivery of the 
3
rd
 pup). 
2.4. Real-time quantitative RT-PCR study 
The cervical samples were stored at 4°C overnight in RNAlater solution (Life Technologies, 
Budapest, Hungary), the supernatant was then removed, and the samples were stored at -70°C 
until total RNA isolation. Total RNA was isolated from samples using the TRI Reagent 
(Molecular Research Centre, Inc., Cincinnati, OH, USA). The quantities of RNA were 
assessed via the ratio of the absorbance at 260 and 280 nm; all samples exhibited ratios in the 
1.6-2.0 range. Amplification of the PCR products (Life Technologies, Hungary) RhoA (Assay 
ID: Rn04219609_m1), Roc1 (Assay ID: Rn00579490_m1), Roc2 (Assay ID: 
Rn00564633_m1) and ß-actin (Assay ID: Rn00667869_m1) as an endogenous control was 
performed with the SensiFAST Probe HiROX One-Step Kit (Bioline, Csertex Ltd., Hungary) 
and the ABI StepOne Real-Time cycler. The following conditions were used for 
6 
 
amplification: 45°C for 10 min, 95°C for 2 min and 40 cycles of 95°C for 5 s, 60°C for 20 s. 
The fluorescence intensities of the probes were plotted against PCR cycle numbers. The 
amplification cycle displaying the first significant increase in the fluorescence signal was 
defined as the threshold cycle. 
2.5. Western blot analysis 
Cervical samples were stored at -70°C until Western blot studies. Cervices were powdered 
with a Sartorius Mikro Dismembrator U (Sartorius, Göttingen, Germany) and homogenized in 
a RIPA Lysis Buffer combined with PMSF solution, sodium orthovanadate solution and 
protease inhibitor cocktail solution (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). 
50 µg of protein per well was subjected to electrophoresis on 4−12% NuPAGE Bis-Tris Gel 
in XCell SureLock Mini-Cell Units (Life Technologies, Budapest, Hungary). Proteins were 
transferred from gels to nitrocellulose membranes using the iBlot Gel Transfer System (Life 
Technologies, Budapest, Hungary). Antibody binding was detected with the WesternBreeze 
Chromogenic Western Blot Immundetection Kit (Life Technologies, Budapest, Hungary). 
The blots were incubated on a shaker with RhoA, Roc1, Roc2 and β-actin monoclonal 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:200) in the blocking buffer. 
The optical density of each immunoreactive band was determined with Kodak 1D Images 
analysis software (Carestream Health, Inc., Rochester, NY, USA). Optical densities were 
calculated as arbitrary units after local area background subtraction. 
2.6. Cervical resistance studies 
Freshly removed whole cervices from non-pregnant (oestrus phase), 20- and 22-day pregnant 
rats were cut into two cervical rings and mounted with their longitudinal axis vertically by 
hooks in an organ bath containing 10 ml de Jongh buffer (137mM NaCl, 3mM KCl, 1mM 
CaCl2, 1mM MgCl2, 12mM NaHCO3, 4mM NaH2PO4, 6mM glucose, ph 7.4). The organ 
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bath was maintained under standard condition (37ºC with carbogen - 95% O2 + 5% CO2–
bubbling). The rings were equilibrated for about 1 hour with a change of buffer solution every 
15 min. The initial tension was set at 1.0 g. RhoA inhibitor (simvastatin) or Rho-kinase 
inhibitors (Y-27632, fasudil) (Sigma-Aldrich, Budapest, Hungary) were added to the organ 
bath in a concentration of 10
-6
M and the cervices were incubated further for 5 min. Then the 
cervical rings were stretched in incremental steps and allowed to relax for 5 min. After every 
5 min, the next initial tension was set, in 1.0 g steps between 1.0 g and 12.0 g. The tension 
was increased manually via the control screw of a gauge transducer and recorded by ISOSYS 
software (MDE Heidelberg, Waldorf, Germany). Evaluation of the cervical resistance was 
carried out such that the initial tension of the cervix was represented versus the stretch after 5 
min. Straight lines were fitted by linear regression and the slopes of the lines were used to 
express the degree of resistance. A steeper slope reflected a higher resistance, the 
physiological decrease in cervical resistance was detectable toward the end of pregnancy 
(pregnancy day 22) (Fig. 1.A-C) (Gaspar et al., 2005; Gál et al, 2009). 
All the experiments were carried out on at least 6 animals, and the values are given as means 
± S.E.M. For statistical evaluations, data were analysed by one-way ANOVA Tukey’s test. 
 
3. Results 
 
3.1. mRNA and protein expression  
Real-time qPCR and Western blot analysis revealed that RhoA and Rho-kinases are expressed 
in rat cervices. The mRNA levels of RhoA were not altered till postpartum day 1 including 
the parturition as well. However, they were increased on postpartum day 3 as compared with 
the non-pregnant cervix and remained high on postpartum day 5 (Fig. 2A). The protein levels 
of RhoA were unchanged till pregnancy day 18. On pregnancy day 20, a significant decrease 
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was found as compared with the non-pregnant level. Such a same low level was also detected 
during parturition. In the postpartum period, the protein expression of RhoA slightly increased 
as compared with the parturient cervix (Fig. 2B and C). 
In case of ROCK I, no change was found in mRNA expression till pregnancy day 20. On day 
22 of pregnancy, a sharp increase was detected that was reduced during labour. Interestingly, 
on postpartum day 1, the mRNA level was raised again but this elevation was not significant 
as compared with the non-pregnant value. The mRNA expression was remained unchanged 
till post-partum day 5 (Fig. 3A). The protein expression of ROCK I decreased on pregnancy 
day 15 as compared with day 5, while a further decrease was measured on day 18 that was 
significant as compared even with the non-pregnant cervix. A significant increase was 
detected on day 22 as compared with pregnancy day 20. The protein expression of ROCK I 
was markedly decreased in parturient cervices. On postpartum day 1 the protein level 
increased as compared with the expression during parturition. No further change was detected 
till postpartum day 5 (Fig. 3B and C). 
The mRNA level of ROCK II did not change markedly from non-pregnant cervix until 
pregnancy day 22, then a sharp decrease was found during parturition. On postpartum day 1, 
the mRNA expression was sharply increased to the level of non-pregnant and 22-day pregnant 
cervices (Fig. 4A). The alteration of the protein expression of ROCK II followed the same 
pattern than that of mRNA alteration (Fig. 4B and C). 
3.2. Cervical resistance studies 
The cervical resistances were continuously decreased towards the end of the gestational 
period. The RhoA inhibitor simvastatin did not alter the resistance of non-pregnant cervices at 
a concentration of 10
-6
M. However, simvastatin enhanced the cervical resistance in days 20 
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and 22 of pregnancy compared with the non-treated values. The cervical resistance-increasing 
effect of the compound was very strong on the last day of pregnancy (Fig.5).  
Similarly, to simvastatin, the ROCK inhibitor Y-27632 did not modified the cervical 
resistance in non-pregnant samples. However, it decreased the resistance of the 20-day 
pregnant cervix but did not alter the 22-day pregnant cervical resistance as compared with the 
non-treated samples (Fig. 6). The other ROCK inhibitor fasudil did not alter either the non-
pregnant or the 22-day pregnant resistance but reduced significantly the cervical resistance in 
days 20 pregnancy (Fig. 7). 
 
4. Discussion 
Adequate condition of the cervix is important for keeping the foetus inside the uterus during 
pregnancy and are needed to facilitate delivery. The cervix consists of an extracellular matrix 
including collagen, elastin, proteoglycans; and a cellular part including smooth muscle, 
fibroblasts, epithelium and blood vessels. The ratios of these components are modulated by 
several factors during pregnancy and parturition, however the regulation of cervical 
maturation is not yet fully clarified (House et al., 2009). 
The RhoA/ROCK signalling pathway plays an important role in the regulation of several 
cellular processes, mainly in smooth muscle contraction by phosphorylation of the myosin 
phosphatase and myosin light chain (Hirano et al., 2003). Recent studies of the monomer 
GTP-binding RhoA and the Rho-kinases have investigated their roles in cardiovascular 
diseases (Loirand et al., 2006), their contributions to the invasion of cancer cells and 
progression (Kamai et al., 2004; Lin et al., 2007; Yoshioka et al., 1999), and their activity in 
uterine contraction (Taggart et al., 2012; Tahara et al., 2002). However, no study has been 
conducted to measure their expression and function in cervical tissue in the rat, especially 
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during pregnancy. Therefore, we investigated the expression of RhoA/ROCKs in rat cervix on 
different days of pregnancy, in the post-partum period and in non-pregnant samples. The 
protein expression of RhoA was significantly reduced 2 days before and during delivery, but 
this kind of alteration was not reflected in the mRNA expression. We found similar 
discrepancy between mRNA and protein expressions in case of ROCK-I, but parallel 
alterations were detected in case of ROCK-II.  It is obvious that the protein levels of ROCKs 
are significantly reduced during parturition suggesting their impact on the final cervical 
ripening and delivery process. Furthermore, the decreased expression level of RhoA during 
labour correlates to the lowest degree of cervical resistance and is concordant with the result 
that RhoA inactivation prevents collagen-I synthesis (Kondrikov et al., 2011). Within 1 day 
after delivery, the RhoA and ROCK protein expressions had recovered to the level of non-
pregnant expressions. These alterations suggest that the higher level of RhoA/ROCK proteins 
may be important for the restoration of cervical tissue that mostly involves the restoration of 
collagen, a process that takes several weeks even in rodents (Nallasamy et al., 2017). 
For functional investigation of the roles of RhoA and ROCKs, we tested the effects of the 
RhoA inhibitor simvastatin and Rho-kinase inhibitors Y-27632 and fasudil on cervical 
resistance. We carried out our experiments on less time points as compared with RT-PCR and 
Western-blot studies. The application of only 3 time points (non-pregnant, and 20- and 22-day 
pregnant cervices) can be justified by 2 reasons. On one hand, according to our earlier result 
the most characteristic drug actions can be detected after day 18 of the gestation period 
(Domokos et al., 2017; Gál et al, 2009).  On the other hand, the isolation of cervix for smooth 
muscle contractility studies is very problematic even at the last day of pregnancy (day 22), but 
that is practically impossible during delivery because of the lack of proper consistency of the 
cervix for organ bath experiments. This is also true for the early phase of postpartum period. 
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This is a limitation of our study, but technically we were not able to gain cervical rings for 
contractility studies during parturition. 
Statins inhibit the geranylgeranylation and the membrane association of RhoA and 
furthermore, they can block the agonist induced RhoA activation (Takemoto and Liao, 2001). 
Interestingly, the results of the in vitro isolated organ bath studies showed that simvastatin 
significantly increased the cervical resistance on pregnancy days 20 and 22. The enhanced 
cervical resistance can the result of the pleiotropic effect of statins that includes the inhibition 
of the secretion of matrix metalloproteinases (MMPs). MMPs have a major role in tissue 
destruction (Luan et al., 2003) and collagen synthesis (Spinale, 2002; Strauss et al., 1996). 
Although simvastatin was reported to decrease MMP-9 activity in human endothelial cells, 
this action was detected after 12 h of preincubation with the compound, only (Izidoro-Toledo 
et al., 2011). In our experiments, the cervices were incubated with simvastatin and the 
ROCKs inhibitors only for 1 h that may be too short time interval to modify MMP activity. 
More likely, simvastatin enhances the smooth muscle contraction in cervical tissue that leads 
to the increase in cervical resistance. However, this action might be independent from the 
RhoA-ROCK pathway and seems unique in the cervix, because simvastatin acts rather as a 
relaxing than a contracting agent in vascular and myometrial smooth muscles (Chen et al., 
2016; Domokos et al., 2017).  
Y-27632 and fasudil are potent non-selective ROCKs inhibitors that cause relaxation of 
smooth muscle by competing with ATP to bind to the catalytic sites in enzymes (Asano et al., 
1989; Ishizaki et al., 2000). Both compounds decreased the resistance of 20-day pregnant 
cervices but did not show such an activity on 22-day pregnant samples. Fasudil reduces the 
production of collagen while it enhances the collagenase activity in hepatic stellate cells 
(Fukushima et al., 2005) and these abilities might contribute to its cervical action. 
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Additionally, it has a relaxant effect on vascular and myometrial smooth muscle (Domokos et 
al., 2017; Shimomura et al., 2004). Y-27632 was shown to reduce the voltage dependent 
potassium (Kv) channels and muscle tone in vascular smooth muscle (Li et al., 2016). This 
effect might contribute to the cervical resistance decreasing effect of the drug, because Kv 
channel expressions have been proved in cervical smooth muscle (de Lera Ruiz and Kraus, 
2015). But it seems more important that Y-27632 is a collagen synthesis inhibitor (Ding et al., 
2012), and its action is even detectable after 30 min of incubation (Yang et al., 2014). That 
kind of quick action may have a crucial a role in the reduced cervical resistance found in our 
organ bath studies after pre-treatments with ROCK inhibitors. The fact that pregnant cervix 
loses its collagen content till labour also support our hypothesis that ROCK inhibitors reduce 
the collagen content quickly and therefore they have no action on cervical resistance on the 
last day of pregnancy because of the lack of cervical collagen. 
Based on these results we suppose that the decrease in RhoA/ROCK expression near 
parturition may have a role in cervical ripening, especially in the final processes leading to 
delivery, and their quick raise in post-partum period indicates their function in cervical 
regeneration process. ROCK inhibitors further reduce the cervical resistance and they can be 
potential drug candidates to treat insufficient cervical ripening late-term pregnancies. The 
cervical resistance increasing effect of simvastatin seems to be independent from its RhoA-
inhibitory action and possibly due to its unique smooth muscle contracting activity in 
pregnant cervix. Simvastatin is contraindicated during pregnancy, however, compounds with 
simvastatin-like action might be new drug candidates for preterm cervical ripening.  
There are only few numbers of clinical trials, that evaluate the inhibition of Rho/Rho-kinase 
pathways using Rho-kinase inhibitors. Fasudil had a positive effect in preventing coronary 
artery spasm in patients with vasospastic angina (Masumuto et al. 2002), enhanced the 
forearm blood flow and reduced forearm vascular resistance in hypertensive patients 
13 
 
(Masumoto et al. 2001). Our results suggest that ROCK inhibitors can be potential drug 
candidates to treat insufficient cervical ripening, but their application in clinical practice can 
be recommended after proving their foetal and maternal safety. 
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Figure 1.A. A representative cervical stress-strain curve of a 22-day-pregnant rat in vitro. The 
series of stretching and relaxation produced a saw-tooth shape record. B. The initial tensions 
were plotted against the tensions recorded after 5 min to get regression lines. The steepness of 
the slopes are in proportion with cervical resistance. C. The comparison of the cervical 
resistance of non-pregnant, 20-day and 22-day pregnant cervices. *: P<0.05; ***: P<0.001. 
Each bar denotes mean ± S.E.M. (standard error); n = 10. ANOVA, Tukey’s test. 
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Figure 2. The mRNA expression (A), a representative gel photo (B) and protein expression 
(C) of RhoA in non-pregnant rat cervix (np), on different days of pregnancy, during 
parturition (dp) and on postpartum days (pp1, pp3, pp5). The level of significance is given in 
two ways. Asterisks represent comparisons to data from non-pregnant cervix. ns: non-
significant; *: P<0.05; **: P< 0.01; ***: P< 0.001. Hashtags represent comparisons to the 
previous investigated days. #: P<0.05; non-significant changes are not indicated. Each bar 
denotes mean ± S.E.M. (standard error); n = 6. ANOVA, Tukey’s test. 
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Figure 3. The mRNA expression (A), a representative gel photo (B) and protein expression 
(C) of ROCK I in non-pregnant rat cervix (np), on different days of pregnancy, during 
parturition (dp) and on postpartum days (pp1, pp3, pp5). The level of significance is given in 
two ways. Asterisks represent comparisons to data from non-pregnant cervix. ns: non-
significant; *: P<0.05; **: P< 0.01; ***: P< 0.001. Hashtags represent comparisons to the 
previous investigated days. #: P<0.05; ##: P< 0.01; ###: P< 0.001; non-significant changes 
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are not indicated. Each bar denotes mean ± S.E.M. (standard error); n = 6. ANOVA, Tukey’s 
test. 
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Figure 4.  The mRNA expression (A), a representative gel photo (B) and protein expression 
(C) of ROCK II in non-pregnant rat cervix (np), on different days of pregnancy, during 
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parturition (dp) and on postpartum days (pp1, pp3, pp5). The level of significance is given in 
two ways. Asterisks represent comparisons to data from non-pregnant cervix. ns: non-
significant; **: P< 0.01. Hashtags represent comparisons to the previous investigated days. #: 
P<0.05; ##: P< 0.01; ###: P< 0.001; non-significant changes are not indicated. Each bar 
denotes mean ± S.E.M. (standard error); n = 6. ANOVA, Tukey’s test. 
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Figure 5. Effects of simvastatin on cervical resistance in the non-pregnant, 20- and 22-day 
pregnant cervices. Simvastatin elicited significant increase in cervical resistance in pregnant 
rats. The significances are given as compared with non-treated (control data). ns: non-
significant; *P< 0.05; ***: P< 0.001. Each bar denotes mean ±S.E.M. (standard error). n=10, 
ANOVA, Tukey’s test. 
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Figure 6. Effects of Y-27632 on the resistances of the non-pregnant, 20- and 22-day pregnant 
cervices. Y-27632 reduced the resistance only in 20-day pregnant cervices. The significances 
are given as compared with non-treated (control) data ns: non-significant; *P < 0.05. Each bar 
denotes mean ±S.E.M. (standard error). n= 10 ANOVA, Tukey’s test. 
 
Figure 7 
 
 
 
 
 
 
 
 
Figure 7. Effects of fasudil on the resistances of the non-pregnant, 20- and 22-day pregnant 
cervices. Y-27632 reduced the resistance only in 20-day pregnant cervices.  The significances 
are given as compared with non-treated (control) data. ns: non-significant; ***P< 0.001. Each 
bar denotes mean ±S.E.M. (standard error). n=10, ANOVA, Tukey’s test. 
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